7-(1-piperazinyl)thieno<2,3-c>pyridine | 106261-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-(1-piperazinyl)thieno<2,3-c>pyridine
• 英文别名: 7-piperazin-1-ylthieno[2,3-c]pyridine；7-(1-Piperazinyl)thieno[2,3-c]pyridine；Thieno[2,3-c]pyridine, 7-(1-piperazinyl)-
• CAS: 106261-29-4
• 化学式: C₁₁H₁₃N₃S
• 分子量: 219.31
• InChiKey: FJGAJXIEIOCUFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  422.2±35.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  56.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(1-piperazinyl)thieno<2,3-c>pyridine 、 3-(4-bromobutyl)thiazolidine-5-spirocyclopentane-2,4-dione 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以60%的产率得到3-[4-(4-Thieno[2,3-c]pyridin-7-yl-piperazin-1-yl)-butyl]-1-thia-3-aza-spiro[4.4]nonane-2,4-dione; hydrochloride
  参考文献：
  名称：

  噻吩并[3,2-c]吡啶和呋喃并[3,2-c]吡啶环：具有潜在抗精神病活性的新药效基团。

  摘要：

  已经合成了两种新的芳基哌嗪衍生物，即4-（1-哌嗪基）噻吩并-和呋喃并[3,2-c]吡啶环系统，并通过四亚甲基链连接到各种酰亚胺环上。发现来自每个系列的目标化合物在阿朴吗啡定型和阿朴吗啡诱导的爬升，Sidman回避反应和条件回避反应中具有显着活性。另外，尽管对于硫代和呋喃并[3，2-c]吡啶衍生物均观察到对5-羟色胺5-HT1和5-HT2受体的强亲和力，但这些分子与多巴胺D2受体的相互作用较弱。每个系列涉及化合物22和33的先导原型的电生理研究表明，这两个分子对A9和A10区域的多巴胺神经元有明显不同的作用。

  DOI：

  10.1021/jm00126a002
• 作为产物：
  描述：

  噻吩并[2,3-c]吡啶-7(6h)-酮 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 7-(1-piperazinyl)thieno<2,3-c>pyridine
  参考文献：
  名称：

  噻吩并[3,2-c]吡啶和呋喃并[3,2-c]吡啶环：具有潜在抗精神病活性的新药效基团。

  摘要：

  已经合成了两种新的芳基哌嗪衍生物，即4-（1-哌嗪基）噻吩并-和呋喃并[3,2-c]吡啶环系统，并通过四亚甲基链连接到各种酰亚胺环上。发现来自每个系列的目标化合物在阿朴吗啡定型和阿朴吗啡诱导的爬升，Sidman回避反应和条件回避反应中具有显着活性。另外，尽管对于硫代和呋喃并[3，2-c]吡啶衍生物均观察到对5-羟色胺5-HT1和5-HT2受体的强亲和力，但这些分子与多巴胺D2受体的相互作用较弱。每个系列涉及化合物22和33的先导原型的电生理研究表明，这两个分子对A9和A10区域的多巴胺神经元有明显不同的作用。

  DOI：

  10.1021/jm00126a002

文献信息

• Indol-3-y-carbonyl-piperidin and piperazin-derivatives
  申请人：Bissantz Caterina

  公开号：US20070027163A1

  公开（公告）日：2007-02-01

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS)
  作者：Akira Asagarasu、Teruaki Matsui、Hiroyuki Hayashi、Satoru Tamaoki、Yukinao Yamauchi、Michitaka Sato

  DOI：10.1248/cpb.57.34

  日期：——

  We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piperazine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure–activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

  我们已准备了一系列哌嗪吡啶衍生物用于治疗肠易激综合征（IBS）。这些化合物通过药效团分析设计，能够同时与血清素亚型1A（5-HT1A）和亚型3（5-HT3）受体结合。异喹啉的氮原子、一个甲氧基和哌嗪是与这些受体结合的药效团的重要组成部分。我们还根据结构-活性关系分析合成了呋喃和噻吡啶衍生物。化合物17c（TZB-20810）对这些受体具有很高的亲和力，同时展现出5-HT1A激动剂活性和5-HT3拮抗剂活性，是治疗IBS方面具有进一步开发潜力的有前景药物。
• Piperidine compounds
  申请人：ADIR ET COMPAGNIE

  公开号：US20020161228A1

  公开（公告）日：2002-10-31

  A compound selected from those of formula (I): 1 wherein: W represents optionally substituted naphthyl, or group of formula Y 2 as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, M, together with carbon of phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same are useful in the treatment of some CNS disorders.

  从式(I)中选择的化合物：其中：W代表可选取代的萘基或式Y2所定义的基团，n表示从1到6的整数，包括Z代表单键，氧或可选取代的氮，A和Q各自代表CH或氮，M与其结合的苯环上的碳一起，代表噻吩基，呋喃基，吡咯基或氧代吡咯基，其异构体和药学上可接受的酸或碱加盐物，以及含有它们的药物制品在治疗某些中枢神经系统疾病方面是有用的。
• Pyrimidine derivatives
  申请人：Sato Michitaka

  公开号：US20070197551A1

  公开（公告）日：2007-08-23

  This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.

  本发明提供了由下式表示的嘧啶衍生物，其中，环A代表碳环基团或杂环基团，X1代表氢、低碳基、氨基等，X2代表氢或低碳基，Y代表直接键或硫或氮，n代表0-4的整数，Ar代表以下式的基团，或其盐，同时表现出5-HT1A激动活性和5-HT3拮抗活性，并且对治疗诸如肠易激综合征等疾病有用。本发明进一步提供了一种IBS治疗方法，其特征在于在体内同时和协同地发挥5-HT1A激动活性和5-HT3拮抗活性，包括给予同时表现出5-HT1A激动活性和5-HT3拮抗活性的5-HT3拮抗剂，或同时给予5-HT1A激动剂和5-HT3拮抗剂，按顺序或间隔给予。
• INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120040990A1

  公开（公告）日：2012-02-16

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基甲酰基哌啶和哌嗪衍生物，其由式I表示：其中残基R1至R3如本文所定义。本发明还涉及含有此类化合物的制药组合物，以及制备该化合物和组合物的方法。本发明还涉及治疗痛经、高血压、慢性心力衰竭、不适当分泌加压素、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。